ReviewThe British journal of dermatology2017
Melanoma in congenital melanocytic naevi.
Review in The British journal of dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 230 citations in OpenAlex.
- Aesthetic techniques for melanocytic nevus management: clinical outcomes, cosmetic satisfaction, and safety-a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium.Journal of the European Academy of Dermatology and Venereology : JEADV · 2018Guideline
- What Is Pediatric Melanoma? Clinical and Genomic Features and the Role of Next-Generation Sequencing in Tumor Classification.International journal of dermatology · 2026Review
- NovoSorb™ biodegradable temporizing matrix for post-excision wound reconstruction in a paediatric giant congenital melanocytic naevus: a case report.Journal of surgical case reports · 2026Article
- Metastatic melanoma in an infant: neoadjuvant radiotherapy and radical neck dissection.Acta oncologica (Stockholm, Sweden) · 2026Article
- Molecular pathology in the diagnosis of cutaneous melanoma.Pathologie (Heidelberg, Germany) · 2026Review
- Living with a rare disease: Why lived experience must shape research.PLoS medicine · 2026Article
- Precision Medicine in Dermatology: MEK Inhibition and MAPK Pathway Modulation for Congenital Melanocytic Nevi.Biomedicines · 2026Review
- Pediatric Melanoma: Emerging Therapies and Ongoing Clinical Trials.Dermatology and therapy · 2026Review
- Mitotic Proliferative Nodule Within a Giant Congenital Nevus: One Case Report and Updated Review.Dermatopathology (Basel, Switzerland) · 2026Review
- Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer.Molecular cancer therapeutics · 2026Article
- Article
- Personalized surveillance in giant congenital melanocytic nevus, including the role of AI, histopathology and MC1R genotyping: A case report.Biomedical reports · 2026Article
- Navigating the Challenges of Metallopharmaceutical Agents: Strategies and Predictive Modeling for Skin Cancer Therapy.Pharmaceutics · 2026Review
- Epigenomic characterization and therapeutic challenges of melanoma arising in giant nevi in pediatric patients.Discover oncology · 2025Article
- Re-evaluation of the Anatomical Distribution Patterns in Large Congenital Melanocytic Nevus.Dermatology practical & conceptual · 2025Article
- Neuroid Overgrowth Proliferative Nodule in Congenital Melanocytic Nevus: A Rare Occurrence.Indian dermatology online journal · 2025Article
- A Case Report of Giant Congenital Melanocytic Nevus Complicated by Minimal Change Disease, With Genetic Analysis.Clinical case reports · 2025Article
- Clinical and histopathological characteristics of melanomas in Asians under age 40.Scientific reports · 2025Article
- Anti-BCL2 therapy eliminates giant congenital melanocytic nevus by senolytic and immune induction.Signal transduction and targeted therapy · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital melanocytic naevi (CMN) are a known risk factor for melanoma, with the greatest risk currently thought to be in childhood. There has been controversy over the years about the incidence of melanoma, and therefore over the clinical management of CMN, due partly to the difficulties of histological diagnosis and partly to publishing bias towards cases of malignancy. Large cohort studies have demonstrated that melanoma risk in childhood is related to the severity of the congenital phenotype. New understanding of the genetics of CMN offers the possibility of improvement in diagnosis of melanoma, identification of those at highest risk, and new treatment options. We review the world literature and our centre's experience over the last 25 years, including the molecular characteristics of melanoma in these patients and new melanoma incidence and outcome data from our prospective cohort. Management strategies are proposed for presentation of suspected melanoma of the skin and the central nervous system in patients with CMN, including use of oral mitogen-activated protein kinase kinase inhibitors in NRAS-mutated tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.